This week in drug discovery (9-13 June)
News round-up for 9-13 June by DDW Senior Digital Content Editor Diana Spencer.
This week’s round-up highlights the vital role of genetics in drug discovery, including new data for an Alzheimer’s gene therapy, the discovery of a genetic target for rejuvenation therapies, and a 13-year follow up on haemophilia gene therapy patients.
The top stories:
Alzheimer’s gene therapy shows promise in preserving brain function
Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease (AD) that could help protect the brain from damage and preserve cognitive function.
Novel single-gene target reverses cellular ageing
Biotechnology company Shift Bioscience has published new research identifying a novel, single-gene target for cellular rejuvenation.
Data shows improved quality of life with CFTR modulators
Vertex Pharmaceuticals has shared data demonstrating the positive clinical and quality of life benefits of treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and in particular, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor).
Haemophilia gene therapy patients thriving a decade later
Patients who received a one-off gene therapy to treat haemophilia are still doing well up to 13 years later, finds a new study from researchers at University College London (UCL), the Royal Free Hospital and St Jude Children’s Research Hospital, Tennessee.
SpliceBio secures $135m to advance gene therapy candidates
SpliceBio has closed a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures.
